tbuckley/cabot-search huggingface dataset:
A qualitative study on the patient's narrative in the progression of chronic venous disease into a first venous leg ulcer: a series of events
Authors: A.M. Meulendijks, M. Welbie, E.P.M. Tjin, L. Schoonhoven, H.A.M. Neumann
Journal: British Journal of Dermatology (2019)

A venous leg ulcer (VLU) has a significant negative impact on quality of life. Prevention of a VLU is not yet imbedded in clinical practice because risk factors for developing a first VLU are not well known.To explore further the progression of chronic venous disease (CVD) into a first VLU from the patient's perspective.A qualitative study using semistructured interviews was conducted among male and female patients with a VLU. Patients from primary and secondary care, under and over 50 years of age, and with first and recurrent VLUs were included. The interviews were transcribed and analysed using a narrative approach to a thematic analysis. Transcripts were organized in chronological order and an iterative process was used to code the transcripts.Four key themes and the connections made between them emerged from the 11 narratives on the progression of CVD towards a first VLU: 'comorbidity', 'mobility', 'work and lifestyle' and 'acknowledgment of CVD'. Comorbidity was linked to reduced mobility and late acknowledgment of CVD. Comorbidity also affected work and lifestyle and vice versa. Work and lifestyle affected mobility and was linked to the acknowledgment of CVD.A reduction in mobility as a result of comorbidity and work and lifestyle occurred before the VLU developed. Patients did not recognize symptoms of CVD and did not acknowledge the chronicity of CVD. Healthcare professionals should be aware of reductions in mobility and the knowledge deficit in patients with CVD. What's already known about this topic? Not all patients with chronic venous disease (CVD) develop a venous leg ulcer (VLU). A patient's quality of life decreases significantly when a VLU develops. Risk factors for the development of a first VLU in patients with CVD are not well known, unlike risk factors for other chronic wounds like diabetic foot ulcer and pressure ulcers. What does this study add? The patient's narrative towards the development of a first VLU, a series of events. Insight into the events (comorbidity, mobility, work and lifestyle) that patients themselves link to the development of a VLU. Insight into the patients' acknowledgment of CVD in the progression of CVD towards a first VLU. What are the clinical implications of this work? More awareness is needed of CVD symptoms among patients and healthcare providers, as well as more awareness for prevention of a VLU in clinical practice. New insights (for further studies) are needed into the concept of mobility and the development of a VLU. Improved patient education and follow-up are needed for patients with CVD.
Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres
Authors: C. Crespillo-Andújar, R. López-Vélez, E. Trigo, F. Norman, M. Díaz-Menéndez, B. Monge-Maillo, M. Arsuaga, J.A. Pérez-Molina
Journal: Clinical Microbiology and Infection (2019)
PDCT-15. EFFICACY AND SAFETY OF BEVACIZUMAB IN TREATING RECURRENT PEDIATRIC LOW-GRADE GLIOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PATIENT OUTCOMES
Authors: Victor Lu, John Welby, David Daniels
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Although rare, the propensity for pediatric low-grade glioma (pLGG) to recur despite upfront intervention presents a management conundrum for clinicians. One novel salvage option is anti-angiogenic bevacizumab, however, its safety and efficacy in this specific demographic is poorly defined. Correspondingly, our aim was to pool systematically-identified metadata in the literature to substantiate the clinical relevance of bevacizumab in treating recurrent pLGG. METHODS Searches of 7 electronic databases from inception to June 2019 were conducted following PRISMA guidelines. Articles were screened against pre-specified criteria. The incidence of loss was then pooled by random-effects meta-analysis of proportions. RESULTS Six pertinent studies described the outcomes of 110 recurrent pLGG patients managed with bevacizumab. While on-treatment, the rate of clinical response was 58% (95% CI, 43–72%), and the rate of radiographic response was 80% (95% CI, 58–96%). Additionally, the rate of serious adverse events (Grade 3 and above) was 11% (95% CI, 5–18%), with proteinuria the most common of those events. By the time patients were off-treatment, the rate of progression was estimated to be 51% (95% CI, 28–74%). Certainty of these results ranged from very low to low. CONCLUSIONS The use of bevacizumab as therapy for recurrent pLGG appears to confer appreciable clinical and radiographic response with relatively low serious adverse events risk while on-treatment. However, the long-term off-treatment benefits of this therapy have yet to be consolidated. Traditional clinical heterogeneity concerns preclude the formalization of any recommendations until larger, more standardized investigations can be performed.
Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation
Authors: Fakiha Siddiqui, Emily Bontekoe, Darko Antic, Debra Hoppensteadt, Grigoris Gerotziafas, Jawed Fareed
Journal: Blood (2019)
Mechanism and effects of pulsatile GABA secretion from cytosolic pools in the human beta cell
Authors: Danusa Menegaz, D. Walker Hagan, Joana Almaça, Chiara Cianciaruso, Rayner Rodriguez-Diaz, Judith Molina, Robert M. Dolan, Matthew W. Becker, Petra C. Schwalie, Rita Nano, Fanny Lebreton, Chen Kang, Rajan Sah, Herbert Y. Gaisano, Per-Olof Berggren, Steinunn Baekkeskov, Alejandro Caicedo, Edward A. Phelps
Journal: Nature Metabolism (2019)
Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women's Health Initiative Study
Authors: Pinkal Desai, Samuel Handelman, Alan Wu, Paul J Christos, Sangmin Lee, Michael B. Samuel, Ellen K. Ritchie, Monica L. Guzman, Rebecca Jackson, Duane C. Hassane, Joann Manson, Alexander Reiner, Michael S. Simon, Gail J. Roboz
Journal: Blood (2019)
Diet and Adaptive Evolution of Alanine-Glyoxylate Aminotransferase Mitochondrial Targeting in Birds
Authors: Bing-Jun Wang, Jing-Ming Xia, Qian Wang, Jiang-Long Yu, Zhiyin Song, Huabin Zhao
Journal: Molecular Biology and Evolution (2019)

Adaptations to different diets represent a hallmark of animal diversity. The diets of birds are highly variable, making them an excellent model system for studying adaptive evolution driven by dietary changes. To test whether molecular adaptations to diet have occurred during the evolution of birds, we examined a dietary enzyme alanine-glyoxylate aminotransferase (AGT), which tends to target mitochondria in carnivorous mammals, peroxisomes in herbivorous mammals, and both mitochondria and peroxisomes in omnivorous mammals. A total of 31 bird species were examined in this study, which included representatives of most major avian lineages. Of these, 29 have an intact mitochondrial targeting sequence (MTS) of AGT. This finding is in stark contrast to mammals, which showed a number of independent losses of the MTS. Our cell-based functional assays revealed that the efficiency of AGT mitochondrial targeting was greatly reduced in unrelated lineages of granivorous birds, yet it tended to be high in insectivorous and carnivorous lineages. Furthermore, we found that proportions of animal tissue in avian diets were positively correlated with mitochondrial targeting efficiencies that were experimentally determined, but not with those that were computationally predicted. Adaptive evolution of AGT mitochondrial targeting in birds was further supported by the detection of positive selection on MTS regions. Our study contributes to the understanding of how diet drives molecular adaptations in animals, and suggests that caution must be taken when computationally predicting protein subcellular targeting.
Aspirin and gastrointestinal bleeding
Authors: J C Krantz
Journal: JAMA (1969)

There is no other over-the-counter (OTC) drug having the widespread use of aspirin. Evoking the well-established analgesic, antipyretic, and anti-inflammatory activities with an amazingly low degree of toxicity, its use has increased in this country to the astounding figure of more than 20 tons daily. The observation that comparatively small daily doses of aspirin may serve as a means of preventing certain types of cardiovascular disasters may lead to even more widespread use of the drug. The most frequent untoward side effect of aspirin is gastric discomfort with or without microbleeding. The amount of bleeding is usually quite small but owing to the long interest of the author in buffered aspirin, it is prudent to determine whether or not this action of aspirin is serious.
Tropical Diseases in Britain
Authors: P. Manson-Bahr
Journal: BMJ (1953)

EDICATLJOURNAL and washing, it was reported, have been successful in the recovery of cells from the upper part of the colon and from the upper part of the small intestine. Ulcerative ColitisDrs. H. E. BACON and H. D. TRIMPI, of Philaaelphia, reported a series of 302 cases of chronic ulcerative colitis treated since 1940; of these, 67 (22.4%) were operated on.Total colectomy with excision of the rectum was performed in 34 patients, and 29 of these have been completely rehabili- tated.Operative mortality was nil.Five carcinomas were discovered in 5 of the 34 excised specimens: of these, four were unsuspected pre-operatively.The authors recommended a two-stage operation, the first consisting of ileostomy and colectomy, and the second of excision of the rectum.Ileostomy was not indicated unless it preceded or accom- panied colectomy.In the opinion of the authors, surgery offered the removal of a precancerous bowel, a cure of the disease, and the arresting of secondary arthritic, kidney, liver, and thrombo-embolic disease.
Treatment of Tetanus
Authors: J. H. McIntyre
Journal: BMJ (1953)

_MEDJtAL JOURNAL may cease to vomit throughout her stay in hospital, thus testing the credulity of her medical attendant.A radiologist needs skill and experience to demonstrate a hiatus hernia.Resolution is rapid in the puerperium, and attempts to make a post-partum diagnosis may be un- successful because of the diminution in size of the hernia, or even its disappearance.Rigler and Eneboe (1935), Bourgeois and Hood (1949), and Schnepp (1943) all com- mented on this feature, our experience of which has been similar.It is not intended to claim that hiatus hernia always causes trouble in pregnancy, or that such a hernia is always responsible for heartburn, vomiting, or haematemesis.We have seen cases illustrating the contrary.It would seem that there is a need for a large-scale investigation to ascertain the role of hiatus hernia in heart- bum and vomiting of pregnancy. SummaryThe association of hiatus hernia with pregnancy is described.Nine cases with symptoms attributed to a hiatus hernia in pregnancy are reported.The literature is briefly reviewed.The need for further investigation is recognized.
The Extent of Neurosis
Authors: R. M. Ladell
Journal: BMJ (1947)

BRITISHcovered with diphtheritic membrane.Throat swabs revealed virulent C. diphtheriae (atypical).Each patient was given 40,000 units of antitoxin intravenously and 60,000 units intramuscularly, and within 24 hours of admission a further 40,000 units intravenously.By Nov. 8 neither showed any improvement and a fatal issue seemed aimost inevitable.50,000 units of penicillin was then administered intramuscularly, followed by doses of 20,000 units 3-hourly, which were continued until Nov. 19 and Nov. 17 respectively.By this time each throat was clean, the swelling of glands had subsided, the nose was free of discharge, and the general condition remarkably improved.Recovery was very gradual, being interrupted by palatal and pharyngeal paralysis in both cases, and by ciliary paralysis in one of them.It was 11 weeks from the onset before the patients were considered fit to sit up, and further convalescence was uneventful.
Multidisciplinary Study Based on Clinical, Electrophysiological and Psycological Evaluations Combined with Advanced Neuroimaging in Gaucher Disease Patients
Authors: Fiorina Giona, Carlo Di Bonaventura, Patrizia Mancini, Gianmarco Tessari, Turchetta Rosaria, Emanuele Cerulli Irelli, Stefano Ferracuti, Teresa Di Giallonardo, Rocco Plateroti, Francesca Atturo, Luisa Cardarelli, Giovanna Palumbo, Marcella Nebbioso, Tiziana Di Pippo, Francesca Caramia
Journal: Blood (2019)
Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)
Authors: John Grainger, James B. Bussel, Michael D. Tarantino, Nichola Cooper, Donald Beam, Jenny M. Despotovic, Alexey A. Maschan, Kejia Wang, Melissa Jeanne Eisen, Charles Bowers
Journal: Blood (2019)
Incidence, Risk Factors and Outcomes of Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome (VOD/SOS) in Children with Severe Thalassemia (ST) Conditioned with Busulfan- Cyclophosphamide (Bu-Cy) Based Regimen
Authors: Stalin Ramprakash, Rajat Kumar Agarwal, C P Raghuram, Pallavi Mehta, Deepa Trivedi, Priya Marwah, Rajpreet Soni, Rakesh Dhanya, Lawrence Faulkner
Journal: Blood (2019)
An Analysis from the WM UK Rory Morrison Registry - How Does Waldenström's Macroglobulinemia Affect Younger Patients?
Authors: Oliver Tomkins, Joshua Bomsztyk, Helen McCarthy, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, Shirley D'Sa
Journal: Blood (2019)
Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
Authors: Zachary D. Epstein-Peterson, Paola Ghione, Alison J. Moskowitz, Parastoo B. Dahi, Ahmet Dogan, Anita Kumar, Matthew J Matasar, Ariela Noy, Miguel-Angel Perales, Doris M Ponce, David J. Straus, Andrew D. Zelenetz, Craig S. Sauter, Steven M. Horwitz
Journal: Blood (2019)
Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)
Authors: Julia Von Tresckow, Paula Cramer, Nisha De Silva, Jasmin Bahlo, Sandra Robrecht, Petra Langerbeins, Anna- Maria Fink, Othman Al-Sawaf, Moritz Fürstenau, Thomas Illmer, Holger Klaproth, Eugen Tausch, Matthias Ritgen, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara F. Eichhorst, Michael Hallek
Journal: Blood (2019)
Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis
Authors: Cinzia Federico, Antonio Sacco, Katia Todoerti, Arianna Giacomini, Gaia C Ghedini, Gaetana Lanzi, Marina Motta, Antonella Anastasia, Vanessa Favasuli, Roberto Ronca, Silvia Giliani, Nicole Bozza, Riccardo Castelli, Giuseppe Rossi, Antonino Neri, Marco Mor, Marco Presta, Aldo M. Roccaro
Journal: Blood (2019)
Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies
Authors: Moritz Bewarder, Gerhard Held, Lorenz Thurner, Klaus Dieter Preuss, Gabi Carbon, Birgit Bette, Konstantinos Christofyllakis, Arne Felbel, Dominic Kaddu-Mulindwa, Niels Murawski, Stephan Stilgenbauer, Frank Neumann
Journal: Blood (2019)
A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia
Authors: Alexandre Bazinet, Ryan N Rys, Claudia M Wever, Amadou Barry, Celia Greenwood, Christian Young, Alma Mendoza, Ida LaPorta, Sylvain Gimmig, François Mercier, Nathalie Johnson
Journal: Blood (2019)
Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information
Authors: Anas Younes, Grzegorz Nowakowski, Allison C. Rosenthal, Lori A. Leslie, Han W. Tun, Matthew A. Lunning, Iris Isufi, Robert Martell, Krish Patel
Journal: Blood (2019)
Watched by Apple
Authors: Edward W. Campion, John A. Jarcho
Journal: New England Journal of Medicine (2019)

After taking over media, social communication, and the consumer economy, the forces of digital innovation are moving into the worlds of medical practice and medical research. Both the power and the limitations of digital innovation in medicine are evident in a report by Perez and colleagues, “Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation,” published in this issue of the Journal.1 The study was sponsored by Apple, and in 8 months it managed to enroll some 419,000 participants through the use of a smartphone application (app). Having an iPhone and an Apple Watch were entry requirements, so the study . . .
Elimination of Acute GvHD with Three Doses of Abatacept Prophylaxis Combined with Post-Transplant Cyclophosphamide after Myeloablative Treosulfan-Based Conditioning in the HLA Identical Sibling and Unrelated (10-12/12) Peripheral Blood Stem Cell Donor Setting: Improved Safety and Efficacy Compared to Alemtuzumab Prophylaxis
Authors: Amit Patel, Jun Yong
Journal: Blood (2019)
SURG-13. DAY-CASE IMAGE-GUIDED BIOPSY FOR BRAIN TUMOURS: A DECADE OF EXPERIENCE FROM A SINGLE NEUROSURGICAL UNIT IN THE UNITED KINGDOM
Authors: Victoria Wykes, Simon McElligott, Joy Roach, Jonathan Duffill, Crispin Weidmann, Paul Grundy
Journal: Neuro-Oncology (2019)

Abstract In the United Kingdom widespread adoption of day-case image-guided biopsy (DIB) for brain tumour has yet to develop. We review a decade of experience of DIB for suspected supra-tentorial brain tumour and recommend discharge criteria for patients post-operatively. 30-day complications, post-operative admissions into hospital and patient satisfaction are examined. METHODS Published protocols and procedures for DIB of brain tumours were used. Tissue samples were sent for fixed histological preparation without intraoperative neuropathological assessment. All patients undergoing an image-guided biopsy for tumour were retrospectively identified from operative logbooks (01/10/2006–30/09/2016), and information recorded from online records. Patients completed satisfaction questionnaires. RESULTS 706 image-guided biopsies for supratentorial tumour were performed of which approximately 60% were identified pre-operatively as candidates for DIB. 92% of DIB patients were successfully discharged 6 hours postoperatively. 4.5% of DIB patients were admitted directly from the day-case unit following identification of a postoperative haematoma &gt;2 cm diameter on CT head performed at 4 hours. 3/401 DIB patients (&lt; 1%) required surgical evacuation for the haematoma, all made a full recovery, with no delay to commencing their oncological management. A diagnostic accuracy of 98% was achieved. Overall 90% of patients were satisfied about the timing of their discharge from hospital and 92.5 % felt they had enough medical support following discharge. DISCUSSION Conscious sedation with enhanced recovery techniques, lack of intra-operative neuropathological analysis and a stream lined service with robust communication between patients, carers/families and the oncology allied medical professionals has ensured that DIB for diagnosis of tumour is safe, reliable and feasible for most patients and is not associated with increased morbidity or mortality. The procedure is well tolerated with good patient satisfaction. We recommend that patients with a good pre-operative functional baseline, requiring a supra-tentorial biopsy are offered day-case surgery in a dedicated unit specialising in this procedure.
Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells
Authors: Isabel Weinhäuser, Diego A Pereira-Martins, Luíse A A Simões, César Alexander Ortiz Rojas, Thiago Mantello Bianco, Cleide Lucia Silva, Mariane Cristina Do Nascimento, Lorena Lobo Figueiredo-Pontes, Antonio R. Lucena-Araujo, Eduardo M Rego
Journal: Blood (2019)
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Authors: Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L Finch, Conrad Oja, Joanna Vergidis, Muhammad Zulfiqar, Katherine Sunderland, Arun A Azad, Christian K Kollmannsberger, Bernhard J Eigl, Krista Noonan, Deepa Wadhwa, Andrew Attwell, Bruce Keith, Susan L Ellard, Lyly Le, Martin E Gleave, Alexander W Wyatt, Kim N Chi
Journal: The Lancet Oncology (2019)
Obesity Does Not Impact Outcome in Patients with AML/MDS Undergoing Allogeneic Transplantation.
Authors: Leandro De Padua Silva, Rima M. Saliba, Marcos de Lima, Grace J. Okoroji, Amin Alousi, Borje Andersson, Chitra Hosing, Elizabeth Sphall, Issa Khouri, Muzaffar Qazilbash, Paolo Anderlini, Partow Kebriaei, Richard E. Champlin, Roy Jones, Sergio Giralt, Uday Popat
Journal: Blood (2007)
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma
Authors: Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur
Journal: Clinical Cancer Research (2019)

To report the 5-year overall survival (OS) landmark and the long-term safety profile of vemurafenib plus cobimetinib (BRAF plus MEK inhibition, respectively) in the BRIM7 study.This phase Ib, dose-finding, and expansion study evaluated combination treatment with vemurafenib and cobimetinib in two cohorts of patients with advanced BRAFV600-mutated melanoma: patients who were BRAF inhibitor (BRAFi)-naïve (n = 63) or patients who had progressed on prior treatment with BRAFi monotherapy [vemurafenib monotherapy-progressive disease (PD); n = 66]. Patients in the dose-escalation phase received vemurafenib at 720 or 960 mg twice daily in combination with cobimetinib at 60, 80, or 100 mg/d for 14 days on/14 days off, 21 days on/7 days off, or continuously. Two regimens were selected for expansion: vemurafenib (720 and 960 mg twice daily) and cobimetinib (60 mg/d 21/7).Median OS was 31.8 months [95% confidence interval (CI), 24.5-not estimable] in the BRAFi-naïve cohort. The landmark OS rate plateaued at 39.2% at years 4 and 5 of follow-up. In the vemurafenib monotherapy-PD cohort, the median OS was 8.5 months (95% CI, 6.7-11.1), and the landmark OS rate plateaued at 14.0% from 3 years of follow-up. No increase was observed in the frequency and severity of adverse events with long-term follow-up. No new toxicities were detected, and there was no increase in the frequency of symptomatic MEK inhibitor class-effect adverse events.A subset of patients with advanced BRAFV600-mutated melanoma treated with a combination regimen of vemurafenib and cobimetinib achieve favorable long-term outcomes.